2. Academic Validation
  3. A Thermostable mRNA Vaccine against COVID-19

A Thermostable mRNA Vaccine against COVID-19

  • Cell. 2020 Sep 3;182(5):1271-1283.e16. doi: 10.1016/j.cell.2020.07.024.
Na-Na Zhang 1,  Xiao-Feng Li 2,  Yong-Qiang Deng 2,  Hui Zhao 2,  Yi-Jiao Huang 2,  Guan Yang 3,  Wei-Jin Huang 4,  Peng Gao 5,  Chao Zhou 2,  Rong-Rong Zhang 2,  Yan Guo 2,  Shi-Hui Sun 2,  Hang Fan 2,  Shu-Long Zu 2,  Qi Chen 2,  Qi He 3,  Tian-Shu Cao 2,  Xing-Yao Huang 2,  Hong-Ying Qiu 2,  Jian-Hui Nie 4,  Yuhang Jiang 5,  Hua-Yuan Yan 5,  Qing Ye 2,  Xia Zhong 5,  Xia-Lin Xue 5,  Zhen-Yu Zha 5,  Dongsheng Zhou 2,  Xiao Yang 3,  You-Chun Wang 6,  Bo Ying 7,  Cheng-Feng Qin 8
Affiliations

Affiliations

  • 1 State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China; School of Medicine, Tsinghua University, Beijing 100084, China.
  • 2 State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.
  • 3 State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China.
  • 4 Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing 102629, China.
  • 5 Suzhou Abogen Biosciences Co., Ltd., Suzhou 215123, China.
  • 6 Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing 102629, China. Electronic address: [email protected].
  • 7 Suzhou Abogen Biosciences Co., Ltd., Suzhou 215123, China. Electronic address: [email protected].
  • 8 State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China. Electronic address: [email protected].
PMID: 32795413 DOI: 10.1016/j.cell.2020.07.024
Abstract

There is an urgent need for vaccines against coronavirus disease 2019 (COVID-19) because of the ongoing SARS-CoV-2 pandemic. Among all approaches, a messenger RNA (mRNA)-based vaccine has emerged as a rapid and versatile platform to quickly respond to this challenge. Here, we developed a lipid nanoparticle-encapsulated mRNA (mRNA-LNP) encoding the receptor binding domain (RBD) of SARS-CoV-2 as a vaccine candidate (called ARCoV). Intramuscular immunization of ARCoV mRNA-LNP elicited robust neutralizing Antibodies against SARS-CoV-2 as well as a Th1-biased cellular response in mice and non-human primates. Two doses of ARCoV immunization in mice conferred complete protection against the challenge of a SARS-CoV-2 mouse-adapted strain. Additionally, ARCoV is manufactured as a liquid formulation and can be stored at room temperature for at least 1 week. ARCoV is currently being evaluated in phase 1 clinical trials.

Keywords

COVID-19; SARS-CoV-2; lipid nanoparticle; mRNA vaccine; mouse-adapted strain; non-human primate; protection.

Figures
Products